Alfalfa

Alfalfa (Medicago sativa L.): A Comprehensive Reference

1. Identity

Botanical and Chemical Names

Medicago sativa L., commonly known as alfalfa, and also called lucerne, is a perennial flowering plant in the legume family Fabaceae. The name "alfalfa" is used primarily in North America, while "lucerne" is the more common name in the United Kingdom, South Africa, Australia, and New Zealand. The name "alfalfa" derives from the Arabic word al-facfacah, meaning "father of all foods," reflecting its high nutritional value. The plant belongs to the order Fabales, subfamily Papilionoideae (tribe Trifolieae), and its accepted full scientific designation is Medicago sativa L. (the "L." denoting the original Linnaean classification).

Botanical Description and Natural Source

Medicago sativa is a perennial, cloverlike, leguminous plant of the pea family, widely grown primarily for hay, pasturage, and silage. It is known for its tolerance of drought, heat, and cold and for the remarkable productivity and quality of its herbage. The plant superficially resembles clover, especially while young, when trifoliate leaves comprising round leaflets predominate; later in maturity the leaflets are elongated. It is currently widely cultivated in central Asia, central Europe, northern Africa, North America, and parts of Australia.

Common Forms and Preparations

All above-ground parts of the plant — leaves, stems, flowers, and seeds — are used medicinally and nutritionally. The dried alfalfa leaf is widely available in herbal shops and health food stores as an herbal tea, tablet, or powder. The seed is often sprouted and eaten in salads and sandwiches. The leaves or seeds are also sold as bulk powdered herb, capsules, and tablets as nutritional supplements in health food stores. Alfalfa is traditionally prepared as a tea; a long cold infusion is commonly used to extract water-soluble vitamins and minerals. Additional commercial forms include standardized extracts, liquid tinctures, and concentrated juice preparations derived from pressed leaves. Sprouts — germinated seeds harvested after several days of growth — constitute a distinct preparation used as a food rather than a supplement.

2. Traditional and Historical Use

Origins and Early Use

Medicago sativa is a well-known nutritious herb with a long history of use as a livestock feed, a medicinal herb and food, and more recently a dietary supplement. Its use probably originated in Asia. The Arabians fed alfalfa to their horses, claiming it made the animals swift and strong, and named the legume "al-fal-fa" meaning "father of all foods." The therapeutic use of alfalfa dates back thousands of years, with evidence of its cultivation appearing in ancient civilizations across multiple continents.

Traditional Chinese Medicine

Alfalfa was used in Traditional Chinese Medicine (TCM), making its first appearance around 200 CE during the Han Dynasty, for digestive system support and to stimulate the appetite. It was revered for its soothing and strengthening properties. Traditional Chinese physicians used young alfalfa leaves to treat disorders of the digestive tract. In TCM, alfalfa is also considered a cooling herb and is used to treat digestive issues, promote lactation, and alleviate symptoms of menopause.

Ayurvedic Medicine

Ayurvedic physicians of India prescribed the leaves and flowering tops for poor digestion. Alfalfa was also considered therapeutic for water retention and arthritis. Medicago sativa has been used as a culinary food in India.

North American Indigenous and Folk Uses

North American Indians recommended alfalfa to treat jaundice and to encourage blood clotting. Native American tribes utilized alfalfa for its medicinal properties, using it as a poultice for wounds and as a tea to treat kidney problems. In traditional American folk medicine, it has been administered as a nutritive tonic.

Broader Traditional Applications

Medicinal uses of alfalfa originated from anecdotal reports that the leaves caused diuresis and were useful in the treatment of kidney, bladder, and prostate disorders. Leaf preparations have been touted for their antiarthritic and antidiabetic activity, for the treatment of dyspepsia, and as an antiasthmatic. Medicago sativa was used traditionally for the treatment of arthritis, kidney problems, fever, as a diuretic, and in an anti-rheumatic, cardiotonic, and lactagogue capacity. The traditional uses for Medicago are extensive, encompassing promotion of diuresis in kidney diseases, improving strength and fertility in livestock, treating diabetes and its long-term consequences such as elevated lipids and obesity, and improving chronic inflammatory disorders from allergies to asthma to arthritis.

3. Key Constituents and Active Compounds

Overview of Phytochemical Classes

An exhaustive survey of the literature reveals that saponins, flavonoids, phytoestrogens, coumarins, alkaloids, amino acids, phytosterols, vitamins, digestive enzymes, and terpenes constitute the major classes of phytoconstituents of this plant. It also contains secondary metabolites such as coumarins, isoflavones, and alkaloids; their content differs with the type of cultivar, tissue, and stage of development.

Saponins

The aerial parts of alfalfa contain mainly glycosides of medicagenic acid substituted at C-3 by glucose or glucuronic acid, zanhic acid, and soyasaponin I tridesmoside. Saponins are among the most pharmacologically relevant constituents of alfalfa. Saponins are a large group of compounds consisting of nonpolar steroidal triterpenoids or aglycones (sapogenins) attached to one or more hydrophilic oligosaccharide moieties via ether or glycosidic ester bonds. Numerous studies indicate that besides protein, M. sativa synthesizes a variety of secondary metabolites, and among the secondary metabolite classes produced by alfalfa, the saponins and flavonoids are of most interest and are well characterized.

Isoflavones and Phytoestrogens

Medicago sativa is one of the herbs rich in phytoestrogenic compounds such as apigenin, luteolin, coumestrol, quercetin, medicarpin, daidzein, and genistein, as well as various vitamins, especially vitamin C. The main isoflavones found in alfalfa are secoisolariciresinol diglucoside, daidzein, secoisolariciresinol, coumestrol, isolariciresinol, hydroxymatairesinol, and matairesinol. The composition of phytochemicals and bioactive compounds also includes phytoestrogens, sterols, tocols, carotenoids, and saturated and unsaturated fatty acids.

Flavonoids and Phenolic Compounds

In the soluble extract of alfalfa leaves, the major compound found by HPLC analysis was catechin, while rutin, epicatechin, and ferulic acid were minor ones. In the bound phenolic extract, the most abundant compounds were ferulic acid and p-coumaric acid, followed by myricetin and apigenin. Alfalfa contains bioactive phytochemicals such as alkaloids, saponins, phenols, tannins, polysaccharides, and phytoestrogens, with antioxidant, anti-inflammatory, immunostimulatory, and anticarcinogenic properties.

Additional Phytoconstituents

Important phytoconstituents found in alfalfa include lutein, soyasapogenol, medicagenic acid, kaempferol, quercetin, myricetin, beta-sitosterol, and stigmasterol. Alfalfa contains bitter alkaloids, coumarins, isoflavonoids (specifically phytoestrogens), protein, and vitamins A, B1, B2, B3, B6, B12, C, D, E, F, K, and U. Common minerals found in alfalfa include calcium, potassium, iron, and phosphorus. Vitamin D2 and vitamin D3 have been isolated and identified from the alfalfa plant.

Non-Protein Amino Acid: L-Canavanine

A non-protein amino acid, L-canavanine, is abundant in alfalfa and is a structural homologue of L-arginine. L-canavanine can be charged by arginyl tRNA synthetase and incorporated into proteins instead of arginine, creating aberrant canavanyl proteins. This compound has significant safety implications discussed in a later section.

Protein Content

Alfalfa has been proposed as an important source of protein for human nutrition due to its high protein content and is a potentially inexpensive alternative animal protein source. Alfalfa is a crop that provides a higher yield of proteins per unit area than any field crop.

4. Established and Proposed Mechanisms of Action

Cholesterol and Lipid Modulation

The cholesterol-lowering effect of alfalfa saponin extract may be attributed to the downregulation of Hmgcr and Acat2, as well as the upregulation of CYP7A1 and LDL-C receptor in the liver of hyperlipidemic rats. Alfalfa saponin extract regulates key genes implicated in cholesterol metabolism, including 3-Hydroxy-3-methylglutaryl CoA reductase (Hmgcr), acyl-CoA cholesterol O-acyltransferase 2 (Acat2), cytochrome P450 family 7 subfamily a polypeptide 1 (Cyp7a1), and the low-density lipoprotein receptor (Ldlr).

Phytoestrogenic Activity

In vitro studies demonstrated that methanolic extracts of alfalfa induced estrogen-dependent proliferation of MCF-7 breast cancer cells and competitively bound to ERβ, confirming phytoestrogenic action through estrogen receptor (ER)-mediated pathways. Co-incubation with the ER antagonist ICI 182,780 reversed this effect, validating receptor-specific involvement. The phytoestrogens in alfalfa — primarily coumestrol, daidzein, genistein, and formononetin — bind to estrogen receptors with lower affinity than endogenous estradiol, producing partial agonist or antagonist effects depending on tissue type and hormonal context.

Antioxidant Mechanisms

Flavonoids, isoflavones, and triterpenoid saponins dominate alfalfa's bioactivity landscape, driving potent antioxidant, anti-inflammatory, antimicrobial, estrogenic, hypolipidemic, and cytotoxic actions through redox modulation, membrane perturbation, receptor engagement, and suppression of NF-κB/MAPK signaling. The bound phenolic extract showed a stronger DPPH radical scavenging capacity (20.8 mg TE/g dry matter) than the soluble fraction (11.4 mg TE/g dry matter).

Hypoglycemic Mechanisms

Sequential extraction with solvents revealed insulin-releasing activity in both methanol and water fractions, indicating a cumulative effect of more than one extract constituent. Researchers concluded the presence of antihyperglycemic, insulin-releasing, and insulin-like activity in Medicago. The hypoglycemic effects of M. sativa are believed to be partly due to its manganese content.

Multi-Organ Protective Effects

Evidence converges on multi-organ protection, improved endothelial tone and lipid profiles, neuroprotection via oxidative-stress quenching, photoprotection afforded by carotenoids and flavones, and selective antitumor effects through apoptosis induction and cell-cycle arrest.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health and Lipid Lowering

The cardiovascular and lipid-modulating effects of alfalfa have the most substantive — though still limited — human clinical evidence of any application area.

Key human study (Mölgaard et al., 1987): Fifteen patients with hyperlipoproteinemia (types IIA, IIB, and IV) were given 40 g of heat-prepared alfalfa seeds three times daily at mealtimes for 8 weeks with an otherwise unchanged diet. The addition of alfalfa seeds to the diet of these 15 patients with type II hyperlipoproteinemia helped normalize serum cholesterol concentrations. Their study found that patients with type II hyperlipoproteinemia experienced significant reductions in LDL-C and apolipoprotein B (Apo B) levels after consuming alfalfa seeds. This is the most-cited human clinical trial for alfalfa and lipids; however, it was a small, short-duration study with only 15 participants and no control group, significantly limiting its conclusions.

Preliminary human data (Malinow et al., 1980): Plasma cholesterol concentrations were reduced in 3 human volunteers during ingestion of diets containing alfalfa seeds for 3 weeks. No signs of toxicity were detected through serum determinations of multiple parameters. This was a case-series report with only 3 subjects and carries very limited evidentiary weight.

Animal evidence: In a rabbit study, dietary alfalfa significantly increased HDL, and the formation of fatty streaks in the aorta, the right and left coronary arteries were significantly reduced under the influence of dietary alfalfa.

Recent RCT (2024): Although alfalfa's cholesterol-lowering effects have been demonstrated in animal models, clinical trial data supporting its efficacy in human dyslipidemia treatment are limited. A randomized controlled trial was conducted from September 2021 to January 2023, involving patients diagnosed with dyslipidemia. Compared to animal studies, the data on the effects of alfalfa powder in human clinical trials are relatively limited and show some degree of heterogeneity.

Overall evidence strength: Preliminary. The mechanistic basis (saponin-mediated cholesterol binding and hepatic gene regulation) is reasonably characterized in animal models, but large, well-controlled human trials are lacking.

5.2 Blood Glucose and Diabetes

Small human study (Salih & Azeez, 2019): Alfalfa is a medicinal plant used traditionally as antidiabetic. A study investigated the short-term antidiabetic action of alfalfa leaves powder in patients with type II diabetes mellitus. Twenty-six volunteers suffering from type II diabetes were involved. A standard test meal was supplemented with 8 g of alfalfa. The results showed that alfalfa leaves significantly (P=0.03) reduced blood sugar two hours after the meal from 344.4 mg/dl to 300.75 mg/dl in the diabetic subjects, in addition to the elevation of serum insulin levels (P=0.02) at 30 minutes.

Animal and in vitro evidence: In streptozotocin-induced diabetic mice, lucerne at 62.5 g/kg in the diet decreased hyperglycemia. Additionally, the aqueous extract of lucerne was associated with an increase in glucose uptake, carbon dioxide production, and glycogenesis.

Overall evidence strength: Weak to preliminary in humans. The single human study was small, unblinded, and measured only acute postprandial effects. Animal studies have suggested Medicago to be effective in the treatment of hyperlipidemia and hyperglycemia; however, more rigorous human studies are required.

5.3 Menopausal Symptoms

Human evidence: One study tested the efficacy of a combination of sage (Salvia officinalis) and Medicago sativa in the treatment of hot flashes and night sweats in 30 menopausal women. Hot flashes and night sweats disappeared in 20 women, 4 women showed good improvement, and the other 6 showed a reduction in symptoms. The authors concluded this herbal combination seemed to have a central, slight antidopaminergic action without side effects and was considered an effective agent in the treatment of menopausal symptoms. However, no clinical trials for menopause using Medicago alone have been reported.

In vitro and mechanistic evidence: Clinical use of alfalfa leaf extract in alleviating neurovegetative menopausal symptoms such as hot flushes and night sweats has been reported. Treatment significantly enhanced prolactin and thyroid-stimulating hormone (TSH) responses to thyrotropin-releasing hormone, indicating central neuroendocrine modulation without altering basal estradiol, LH, or FSH levels.

Overall evidence strength: Very weak for alfalfa alone. The combination study was small, lacked a placebo arm, and cannot isolate alfalfa's contribution. The phytoestrogenic rationale is mechanistically plausible but not confirmed in controlled human trials.

5.4 Bone Health

Combined with the calcium, vitamin K, vitamins D2 and D3, and other nutrients and constituents that the plant naturally contains, Medicago may support bone density and help alleviate menopausal symptoms in part because of its phytoestrogenic activity. Genistein has been shown to stimulate bone formation, inhibit bone resorption, and prevent bone loss in ovariectomized rat models. Genistein at 54 mg/day for 1 or 2 years has also been demonstrated in a few randomized, double-blind, placebo-controlled studies to be effective in preventing bone loss in postmenopausal women. These genistein studies, however, used pure genistein isolates — not alfalfa extracts — and their applicability to alfalfa supplementation is indirect.

Overall evidence strength: Insufficient for alfalfa per se. Evidence for individual constituents such as genistein is more developed, but studies using whole alfalfa preparations for bone outcomes in humans are absent from the published literature.

5.5 Antioxidant and Anti-Inflammatory Activity

Evidence here is largely preclinical. Alfalfa is a tonic plant rich in proteins, vitamins, and minerals that is used to treat many diseases due to its pharmacological properties such as anti-inflammatory and antioxidant activities. Besides the antioxidant role of alfalfa, its beneficial effects on some diseases such as diabetes, thalassemia, various cancers, renal disorders, and hypercholesterolemia have been identified. These observations, however, derive predominantly from animal and in vitro studies. Controlled human trials examining antioxidant or anti-inflammatory outcomes from alfalfa supplementation specifically are not well represented in the peer-reviewed literature.

Overall evidence strength: Preclinical (animal and in vitro) only; human evidence insufficient.

5.6 Antimicrobial and Antifungal Activity

In vitro studies have identified antimicrobial and antifungal compounds in alfalfa root extracts. Pharmacological reports reveal that alfalfa is used as a neuroprotective, hypocholesterolemic, antioxidant, antiulcer, antimicrobial, hypolipidemic, and estrogenic agent. These antimicrobial findings are limited to laboratory conditions; clinical human evidence is absent.

Overall evidence strength: In vitro only; no human clinical evidence.

5.7 Male Reproductive Health

One randomized clinical trial with 60 participants examined the effect of Medicago sativa seed powder (6 grams per day) along with vitamin E (100 IU) in men with idiopathic infertility. After three months, researchers found improved sperm total count, morphology, and motility. Because vitamin E was co-administered, the independent contribution of alfalfa cannot be isolated from this study.

Overall evidence strength: Preliminary; single small RCT with a confounding co-intervention.

6. Body Systems Associated With Alfalfa

• Cardiovascular system: Pharmacological reports document its use for atherosclerosis, heart disease, and stroke.
• Endocrine and reproductive system: Phytoestrogenic activity via isoflavone binding to estrogen receptors; traditional use for menopausal symptoms and lactation promotion.
• Metabolic and glycemic regulation: Beneficial effects on diabetes and hypercholesterolemia have been identified.
• Musculoskeletal system: Traditional use for arthritis and bone support linked to mineral content (calcium, phosphorus) and vitamin K content.
• Digestive system: Traditional Chinese physicians used young alfalfa leaves to treat disorders of the digestive tract.
• Urinary system: Medicinal uses include reports of diuresis and usefulness in the treatment of kidney, bladder, and prostate disorders.
• Immune system: Contains immunostimulatory polysaccharides; also contains L-canavanine which has immunomodulatory (and potentially immunotoxic) properties.
• Hepatic system: Animal studies suggest hepatoprotective effects, and alfalfa saponins regulate hepatic cholesterol metabolism genes.

7. Dosage Forms and Dosages Reported in Studies

A general dosing regimen cited in the literature is 5 to 10 g of the dried herb taken 3 times daily. Seeds for high cholesterol may be taken at a dose of 40 g three times daily.

• Dried herb (leaf/aerial parts): A general dosing regimen is 5 to 10 g of the dried herb taken 3 times daily.
• Seeds for hypercholesterolemia (Mölgaard et al., 1987): Fifteen patients were given 40 g of heat-prepared alfalfa seeds 3 times daily at mealtimes for 8 weeks.
• Alfalfa leaf powder for blood glucose (Salih & Azeez, 2019): A standard test meal was supplemented with 8 g of alfalfa leaves powder.
• Seed powder for male infertility: One randomized clinical trial examined the effect of Medicago sativa seed powder at 6 grams per day.
• Ethanolic extract: Tavakkoli Ardakani found alfalfa ethanolic extract at 750 mg/day was used in one study.

There is not enough reliable information to definitively establish what an appropriate standardized dose of alfalfa might be for any specific indication. Dosages used across studies vary substantially by preparation form (whole herb, seed, extract), the condition under investigation, and the method of extraction or processing.

8. Safety Considerations and Drug Interactions

8.1 L-Canavanine and Autoimmune Risk

This is the most well-documented and serious safety concern associated with alfalfa. Alfalfa sprouts can induce systemic lupus erythematosus (SLE) in monkeys. This property has been attributed to the non-protein amino acid constituent L-canavanine. Occurrence of autoimmune hemolytic anemia and exacerbation of SLE have been linked to ingestion of alfalfa tablets containing L-canavanine. L-canavanine has dose-related effects in vitro on human immunoregulatory cells, which could explain its lupus-inducing potential.

The classical explanation is that alfalfa contains L-canavanine which is thought to cause SLE via dysregulation of T and B lymphocytes in the immune system. Alfalfa might cause the immune system to become more active, which could increase the symptoms of autoimmune diseases such as multiple sclerosis (MS), lupus (SLE), and rheumatoid arthritis (RA).

8.2 Interaction with Warfarin (Anticoagulants)

Alfalfa contains large amounts of vitamin K. Vitamin K is used by the body to help blood clot. Warfarin (Coumadin) is used to slow blood clotting. By helping the blood clot, alfalfa might decrease the effectiveness of warfarin. Alfalfa contains a large amount of vitamin K, which can reduce the anticoagulant activity of warfarin. Alfalfa was part of the original research on vitamin K metabolism and was one of the first substances from which vitamin K was synthesized. This interaction is rated as major in clinical interaction databases, meaning the combination should generally be avoided.

Signals of interactions between warfarin and alfalfa (among other dietary supplements) have been detected by analysis of structured clinical data and unstructured clinical notes from the University of Minnesota Clinical Data Repository.

8.3 Estrogenic Interactions

Birth control pills and exogenous estrogen preparations carry a moderate interaction rating with alfalfa. Some birth control pills contain estrogen. Alfalfa might have some of the same effects as estrogen, but alfalfa is not as strong as the estrogen in birth control pills. Large amounts of alfalfa might have some of the same effects as estrogen, though even large amounts of alfalfa are not as strong as estrogen pills. Taking alfalfa along with estrogen pills might decrease the effects of estrogen pills.

8.4 Antidiabetic Drugs

Alfalfa may interact with medications for diabetes (antidiabetes drugs), medications that decrease the immune system (immunosuppressants), and medications that increase sensitivity to sunlight (photosensitizing drugs). The potential additive hypoglycemic effect raises concerns about combination with insulin or oral antidiabetic agents, though direct human clinical evidence for this interaction is limited.

8.5 Immunosuppressants

Because alfalfa may stimulate immune function through its polysaccharide and phytoestrogen components, it may antagonize the effects of immunosuppressant medications. A case report in the transplant literature documented an acute renal transplant rejection possibly related to herbal medication use including alfalfa. Alfalfa might cause the immune system to become more active, which could increase the symptoms of autoimmune diseases.

8.6 Photosensitivity

Alfalfa seed products may cause reactions similar to the autoimmune disease lupus erythematosus. Alfalfa might also cause some people's skin to become extra sensitive to the sun. This photosensitizing effect has been attributed to the psoralen-type coumarins present in the plant.

8.7 Microbiological Safety of Sprouts

Alfalfa sprouts, if not grown carefully, may be contaminated with salmonella. This represents a food safety concern distinct from any pharmacological property of the plant itself, and multiple documented outbreaks of Salmonella and E. coli infections associated with raw sprout consumption have been reported in public health literature.

8.8 Pregnancy and Lactation

Using alfalfa in amounts larger than what is commonly found in food is possibly unsafe during pregnancy and breast-feeding. Alfalfa might act like estrogen in the body. The phytoestrogenic activity of alfalfa's isoflavones raises theoretical concerns about hormonal disruption during fetal development and in hormone-sensitive individuals.

8.9 General Toxicity and Long-Term Safety

Alfalfa leaves are possibly safe when used short-term. Taking alfalfa in high doses or long-term is likely unsafe. Long-term use might cause reactions similar to the autoimmune disease called lupus in some people. Heterogeneity in extraction protocols, lack of phytochemical standardization, and scarce pharmacokinetic data represent ongoing gaps in the safety characterization of alfalfa preparations.

9. Current State of Evidence: Summary

Alfalfa (Medicago sativa) has a well-characterized phytochemistry and a mechanistically plausible rationale for several of its traditional applications, particularly lipid reduction (via saponins), phytoestrogenic activity (via isoflavones), and antioxidant effects (via phenolics and flavonoids). However, the human clinical evidence base remains sparse and methodologically limited. Compared to animal studies, the data on the effects of alfalfa preparations in human clinical trials are relatively limited and show some degree of heterogeneity. Heterogeneity in extraction protocols and lack of phytochemical standardization further complicate cross-study comparison. The most clinically significant concern is the well-documented L-canavanine-mediated autoimmune risk, particularly in individuals with pre-existing SLE or related conditions, and the major drug interaction with warfarin mediated by alfalfa's high vitamin K content.

References

• Raeeszadeh M. et al. "The Antioxidant Properties of Alfalfa (Medicago sativa L.) and Its Biochemical, Antioxidant, Anti-Inflammatory, and Pathological Effects on Nicotine-Induced Oxidative Stress in the Rat Liver." Oxidative Medicine and Cellular Longevity, 2022. PMC8976666.
• Horvat D. et al. "Characterization of Forage Quality, Phenolic Profiles, and Antioxidant Activity in Alfalfa (Medicago sativa L.)." Plants, 2022. PMC9612203.
• Joolaei Ahranjani et al. "Bioactive Phytochemical Compounds in Medicago sativa L. (Alfalfa): A Systematic Review." Food Frontiers, 2025–2026.
• Nutraceutical Properties of Medicago sativa L., Agave spp., Zea mays L. and Avena sativa L.: A Review of Metabolites and Mechanisms. Metabolites, MDPI, 2022.
• Bora KS, Sharma A. "Phytochemical and Pharmacological Potential of Medicago sativa: A Review." Pharmaceutical Biology, 2011.
• "The effects of alfalfa powder combined with health education on patients with dyslipidemia: A randomized controlled trial." Journal of Ethnopharmacology, ScienceDirect, 2024.
• Malinow MR, McLaughlin P, Stafford C. "Alfalfa seeds: effects on cholesterol metabolism." Experientia, 1980. PMID 7379953.
• Mölgaard J, von Schenck H, Olsson AG. "Alfalfa seeds lower low density lipoprotein cholesterol and apolipoprotein B concentrations in patients with type II hyperlipoproteinemia." Atherosclerosis, 1987;65:173–179.
• "The Regulation of Alfalfa Saponin Extract on Key Genes Involved in Hepatic Cholesterol Metabolism in Hyperlipidemic Rats." PMC3914959.
• "Effects of alfalfa on lipoproteins and fatty streak formation in hypercholesterolemic rabbits." ARYA Atherosclerosis, 2008. PMID 18930871.
• Alcocer-Varela J. et al. "Effects of L-canavanine on T cells may explain the induction of systemic lupus erythematosus by alfalfa." Arthritis & Rheumatism, 1985;28:52–57.
• "Role of non-protein amino acid L-canavanine in autoimmunity." Autoimmunity Reviews, 2006.
• Restorative Medicine Monograph: Alfalfa (Medicago sativa).
• Drugs.com Natural Products Database: Alfalfa — Uses, Benefits & Dosage.
• RxList: Alfalfa — Health Benefits, Side Effects, Uses, Dose & Precautions.
• Hines LE. et al. "Detecting Signals of Interactions Between Warfarin and Dietary Supplements in Electronic Health Records." PMC5760175.
• Salih BA, Azeez KO. "Antidiabetic Action of Alfalfa (Medicago sativa) Leaves Powder on Type II Diabetic Patients." Polytechnic Journal, 2019;9(1):23–25.
• "Medicago sativa: A historical ethnopharmacology and etymological study of the alfalfa." ResearchGate, 2011.
• PeaceHealth Health Information Library: Alfalfa.
• Pharmacy Times: "Warfarin-Supplement Interactions to Watch for."